Market Place
Sourcing Support
Fate Therapeutics Reports Q2 2024 Results And Business Updates
13 Aug 2024 //
GLOBENEWSWIRE
Enforcement Report - Week of April 10, 2024
10 Apr 2024 //
FDA
Fresenius Kabi Further Expands Oncology Portfolio
28 Feb 2024 //
BUSINESSWIRE
RK Pharma`s Generic Cyclophosphamide Receives Approval in the U.S.
18 Dec 2023 //
FDA
Zydus Pharma`s Generic Cyclophosphamide Receives Approval in the U.S.
13 Dec 2023 //
FDA
Sagent`s Generic Cyclophosphamide Receives Approval in the U.S.
17 Jul 2023 //
FDA
Ibrutinib Plus Chemoimmunotherapy Fails to Improve PFS in Pretreated FL, MZL
20 Jun 2023 //
ONCLIVE
FDA adcomm votes 11-2 to expand Roche`s Polivy label in DLBCL
10 Mar 2023 //
ENDPTS
FDA Confirms Paragraph IV Patent Litigation for Cyclophosphamide Injection
23 Feb 2023 //
FDA
Stem cell transplants may slow disability progression in MS
22 Dec 2022 //
EUROPEANPHARMACEUTICALREVIEW
Genentech Presents Data for Polivy at ASH 2022
11 Dec 2022 //
BUSINESSWIRE
Alembic Pharmaceuticals gets final USFDA approval for Cyclophosphamide capsules
14 Nov 2022 //
HEALTH ET
Alembic`s Generic Cyclophosphamide Receives Approval in the U.S.
10 Nov 2022 //
FDA
Xellia`s Generic Cyclophosphamide Receives Approval in the U.S.
18 Oct 2022 //
FDA
Genentech lymphoma treatment gets FDA approval
16 Aug 2022 //
LABIOTECH
IMV Inc. Announces Second Quarter 2022 Financial and Operational Results
11 Aug 2022 //
BUSINESSWIRE
SMC approve Johnson & Johnson’s systemic light chain amyloidosis therapy
10 Aug 2022 //
PHARMA TIMES
SMC accepts first licensed treatment for newly diagnosed AL amyloidosis
09 Aug 2022 //
PHARMAFILE
EC approves Roche’s Polivy combination in previously untreated diffuse LBCL
26 May 2022 //
EXPRESS PHARMA
FDA Confirms Paragraph IV Patent Litigation for Cyclophosphamide
21 Apr 2022 //
FDA
VFMCRP receives EU approval for Tavneos in ANCA-associated vasculitis
19 Jan 2022 //
BUSINESSWIRE
Progression-Free Survival Boost Noted With Polatuzumab Vedotin Plus R-CHP
17 Dec 2021 //
CANCERNETWORK
EMA CHMP Gives Positive Recommendation for Tavneos in ANCA Vasculitis
12 Nov 2021 //
GLOBENEWSWIRE
CRISPR Therapeutics` CAR-T Cancer Therapy Shows Early Promise
13 Oct 2021 //
BIOSPACE
Lurbinectedin/Doxorubicin Comparable to Standard of Care for SCLC, But Safer
10 Sep 2021 //
ONCLIVE
Aurobindo’s, Eugia Pharma gets US FDA nod for cyclophosphamide injection
28 Aug 2021 //
PHARMABIZ
CBMG` Novel CD19/CD20 Bi-specific CAR-T Cell Product Shows Promising Results
10 Jun 2021 //
PRNEWSWIRE
CBMG` Novel Anti-CD20 CAR-T Cell Therapy Shows Promising Safety and Efficacy
10 Jun 2021 //
PRNEWSWIRE
Belimumab Plus Standard Lupus Nephritis Therapy Improves Renal Responses
09 Jun 2021 //
RENAL & NEURO NEWS
Salarius Pharma Presents New Research Data at ASCO 2021 Annual Meeting
07 Jun 2021 //
GLOBENEWSWIRE
Increased Clarity On The Role Of Immunotherapy In Early Tnbc
20 Sep 2020 //
ESMO
Janssen seeksFDA approval for Darzalex Faspro to treat patients with amyloidosis
12 Sep 2020 //
PHARMABIZ
Partner begins phase II study of Leukine in T cell replete HLA-mismatched
12 Jun 2020 //
PHARMABIZ
EHA25Virtual: Study of Subcutaneous Daratumumab Shows Improved Clinical Outcomes
12 Jun 2020 //
PRNEWSWIRE
European Commission Approves ADCETRIS® (brentuximab vedotin)
14 May 2020 //
BUSINESSWIRE
EMA committee recommends approval of Takeda’s Adcetris in combo
01 Apr 2020 //
PHARMABIZ
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin)
31 Mar 2020 //
PRESS RELEASE
BeyondSpring commences late-stage study of Plinabulin for preventing chemo
23 Oct 2019 //
SEEKINGALPHA
Kiadis Pharma provides regulatory update on ATIR101
18 Oct 2019 //
PRESS RELEASE
Seattle Genetics investors breathe a sigh of relief as Adcetris posts 30% growth
17 Jul 2019 //
FIERCE PHARMA
Unum Plunges After FDA Places Another Clinical Hold on Company Asset
04 Jul 2019 //
BIOSPACE
Copycats wanted: Pfizer, AZ and more under threat as China solicits generics
21 Jun 2019 //
FIERCE PHARMA
Takeda suffers another setback in its quest to expand myeloma drug’s reach
06 Jun 2019 //
ENDPTS
Novartis abandons effort for U.S. approval of rituximab
03 Nov 2018 //
REUTERS
Seattle Genetics Announces results of Broad ADCETRIS® (Brentuximab Vedotin)
01 Nov 2018 //
BUSINESSWIRE
Celltrion & Teva Announce FDA ODAC Recommends CT-P10 Approval
11 Oct 2018 //
BUSINESSWIRE
FDA Recommends Use of Placebo Only in Certain Oncology Trials
24 Aug 2018 //
RAPS
Need a placebo control group for cancer drug study- FDA
23 Aug 2018 //
ENDPTS
Epizyme Halts Phase II Trial of Tazemetostat in DLBCL
02 Aug 2018 //
GEN
Accord’s biosimilar Pelgraz poised for approval
31 Jul 2018 //
PHARMAPHORUM
Adaptimmune Announces Safety Review from 1-Bln Cell Dose Cohort in MAGE-A10
18 Jul 2018 //
GLOBENEWSWIRE
AbbVie, J&J’s Imbruvica fails to target in B-Cell lymphoma trial
12 Jul 2018 //
PHARMA TIMES
AbbVie Stock Drops After Disappointing Clinical Trial Update
12 Jul 2018 //
BIOSPACE
Amneal Pharma`s Generic Cyclophosphamide Receives Approval In US
31 May 2018 //
FDA
Enforcement Report - Week of May 16, 2018
16 May 2018 //
FDA
Amerigen Pharma`s Generic Cyclophosphamide Receives Approval In US
22 Mar 2018 //
FDA
FDA expands approval of Adcetris for Tx of Stage3/4 classical Hodgkin lymphoma
20 Mar 2018 //
PRNEWSWIRE
Juno notches positive data for second-chance CAR-T JCAR017
05 Jun 2017 //
FIERCE BIOTECH
EU Commission Grants Marketing Authorization for Arzerra
12 Dec 2016 //
GLOBENEWSWIRE
